Skip to main content

Table 1 Baseline Characteristics (SD: standard deviation; ESKD: end-stage renal disease; CVC: central venous catheter; AVF: arteriovenous fistula; AVG: arteriovenous graft; RAAS: renin angiotensin aldosterone system; CCB: calcium channel blocker)

From: Retrospective single center cohort study: effect of intensive home hemodialysis on right ventricular systolic pressure and clinical outcomes

 

All patients

(n = 108)

Age, years, mean ± SD

45 ± 13

Male sex, n (%)

67 (62)

Race, n (%)

 - White

58 (54)

 - Asian

15 (14)

 - Black

14 (13)

 - Other

20 (19)

BMI, kg/m2, mean ± SD

24.5 ± 5.5

Cause of ESRD, n (%)

 - Diabetic nephropathy

12 (11)

 - Glomerulonephritis

44 (40)

 - Hypertensive nephrosclerosis

7 (6)

 - Polycystic kidney disease

10 (9)

 - Other

35 (32)

Type of renal replacement therapy prior to intensive hemodialysis, n (%)

 - Chronic kidney disease not on dialysis

32 (30)

 - Non-intensive hemodialysis

39 (36)

 - Peritoneal dialysis

11 (10)

 - Renal transplantation

26 (24)

Initial access type, n (%)

 - CVC

55 (51)

 - AVF

43 (40)

 - AVG

10 (9)

Duration of ESKD, years, median (IQR)

2 (0.3–12)

Hours of dialysis per week, mean ± SD

35 ± 7.3

Total follow up in years, mean ± SD

4.0 ± 2.2

Time between echocardiograms in years, mean ± SD

3.3 ± 2.0

Co-existing medical conditions, n (%)

 - Diabetes

27 (25)

 - Smoking history

20 (19)

 - Hypertension

93 (86)

 - Coronary artery disease

10 (9)

 - Peripheral vascular disease

6 (6)

 - Stroke

6 (6)

Baseline blood pressure therapy

 - Number of antihypertensives, mean ± SD

1.8 ± 1.3

 - Patients on > 2 antihypertensives, n (%)

28 (26)

 - RAAS blockade/CCB/β-blocker, %

47/52/51

1-Year blood pressure therapy

 - Number of antihypertensives, mean ± SD

0.8 ± 1.0

 - Patients on > 2 antihypertensives, n (%)

6 (6)

 - RAAS blockade/CCB/β-blocker, %

17/17/43